Abstract library

91 results for "post-PRRT".
#2013 Optimizing Reconstruction Algorithm to Improve Quality of Post-PRRT Yittrium-90 PET Scan
Introduction: 90Y is commonly used in PRRT for NET. It has no gamma photon in its emission that significantly limits post-therapy imaging and dosimetry. Other than Bremsstrahlung imaging which bears hereditary drawbacks of poor resolution, PET scan has been used for post-PRRT imaging. However, in daily clinical practice, due to extremely low abundance of positron emission per decay and patient’s intolerability of prolonged scan time, it is very difficult to obtain a scan with decent quality.
Conference: 15th Annual ENETS conference (2018)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Doctor Sean X Yan
Authors: Yan S X, Lim G K
#712 A Retrospective Analysis of Safety and Efficacy of Everolimus in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients That Showed Progression after PRRT
Introduction: GEP-NET patients have been treated successfully with SSAs. Upon progression, peptide receptor radiotherapy (PRRT) with 177Lu-octreotate is successful. PRRT is not unlimited. Some patients became refractory after therapy. There is a high medical need. Everolimus (mTOR inhibitor) is a promising therapy for progressive G1/G2 GEP-NETs, with well-established safety. Everolimus has shown efficacy in patients with (non-)PNET (RADIANT-2/-3). However, toxicity data of Everolimus after PRRT is lacking.
Conference: 10th Annual ENETS Conference (2013)
Category: Medical treatment - Targeted therapies
Presenting Author: drs. Kimberly Kamp
#1471 Chemotherapy for Stage IV Sporadic Pancreatic Neuroendocrine Tumors (pNET): Are Partial Responses to Post-first Line Chemotherapy Predictable by Response/Type of First Line Chemotherapy?
Introduction: Three types of chemotherapy are recommended for stage IV pancreatic neuroendocrine tumors (pNETs): streptozocin (STZ)-, dacarbazine (DCZ)- and oxaliplatin (OX)-based. Whether cross resistance exists is unknown.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Chemotherapy
Presenting Author: Medical Doctor Vincenzo Marotta
Authors: Marotta V, Malka D, Walter T, Do Cao C, ...
#547 Insulin Autoimmune Syndrome Mimicking Insulinoma: A Challenging Diagnosis
Introduction: Insulin autoimmune syndrome (IAS) is a rare condition characterized by hypoglycemia due to autoantibodies against endogenous insulin. It is correlated, in approximately 50% of cases, to specific drugs intake. Hypoglycemia occurs typically during the late post-prandial period.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Prof Laura De Marinis
#1812 Correlation of Plasma (p) and Urine (u) 5-HIAA Levels in Patients (pts) with Carcinoid Syndrome (CS) – Post-Hoc Analyses from the TELESTAR Study
Introduction: Telotristat ethyl (TE) is an oral tryptophan hydroxylase inhibitor in development for treating CS symptoms. During the double-blind treatment [DBT] period of the phase 3, 12-week, placebo-controlled TELESTAR study, TE was well tolerated and significantly reduced bowel-movement frequency and u5-HIAA levels compared with placebo (PBO) in NET patients with CS treated with a SSA.
Conference: 14th Annual ENETS conference (2017)
Category: Medical treatment - Others
Presenting Author: Marianne Pavel
#1856 Relationship Between Symptoms and HRQoL Benefits in Patients (pts) with Carcinoid Syndrome (CS): A Post-Hoc Analysis of Telotristat Ethyl (TE) TELESTAR Trial
Introduction: TELESTAR previously demonstrated the efficacy and safety of TE in pts with CS experiencing >4 Bowel Movements (BM) per day despite stable-dose somatostatin analog therapy. Significantly higher rates of Durable Response (DR, predefined as Bowel Movement (BM) frequency reduction ≥30% from baseline for ≥50% of the 12 week double blind period) were observed with TE (TE 250mg: 44%, TE 500mg: 42%) vs placebo (20%).
Conference: 14th Annual ENETS conference (2017)
Category: Medical treatment - Others
Presenting Author: Florence Marteau
#252 Y90-DOTATATE in Gastroenteropancreatic neuroendocrine tumors (GEP-NETs): Survival Following Different Indications for Treatment
Introduction: Peptide Receptor Radionuclide Therapy (PRRT) is an increasingly used treatment for GEP -NETs but there is limited data on indications, efficacy and survival.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr Mohid S Khan
#310 Relationship Between Dose and Molecular Response After Peptide Receptor Radionuclide Therapy (PRRNT) in Neuroendocrine Tumors: Preliminary Results
Introduction: PRRNT is an effective therapy option in well-differentiated neuroendocrine tumors. However, there exists no study showing the ability to predict response to PRRNT on a pretherapy Ga-68 SMS-R PET/CT.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Prof. Dr. med. Richard P Baum
Keywords: dose, molecular, response
#1299 Clinical Value of Somatostatin Receptor Scintigraphy in the Management of Medullary Thyroid Carcinoma
Introduction: Medullary Thyroid Carcinoma (MTC) is a rare form of thyroid cancer. It represents 5 to 10 % of these cancers. MTC grows from specialized thyroid cells called para-follicular cells, or C-cells that secrete a hormone called calcitonin. Its prognosis is usually good. Recurrences can occur, requiring lifelong surveillance.
Conference: 13th Annual ENETS conference (2016)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Dorra Ben Sellem
#57 Clinical and demographic characteristics in patients newly diagnosed with neuroendocrine tumors (NET)
Introduction: Neuroendocrine tumors (NETs) are tumors that form from cells that release hormones in response to a signal from the nervous system. These tumors may secrete higher-than-normal amounts of hormones, which can cause many different symptoms.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Chi-Chang Chen